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Glutamate and tumor-associated epilepsy
Harald Sontheimer
For many patients an unexplained seizure is 
among the earliest symptoms of a growing primary 
brain tumor. These tumors originate from glial cells or 
their progenitors in the brain and are often referred to as 
glioma. In approximately 30% of patients seizures recur 
spontaneously giving rise to tumor associated epilepsy 
[1].  While  these  fits  are  generally  well  controlled  by 
antiepileptic medications, in some instances the tumor-
associated epilepsy remains refractory to medical 
treatment [2] and seriously impedes a patient’s quality of 
life. It is commonly assumed that seizures are caused by 
an imbalance of excitatory glutamatergic and inhibitory 
GABAergic neurotransmission. Such imbalances may 
involve structural changes in the brain or changes in the 
receptor composition of hyperexcitable brain regions. 
These alterations may be congenital or caused by acute 
or chronic insults. Tumor-associated epilepsy falls into 
the latter category, and it had long been assumed that 
the growing tumor mass exerts a pro-convulsive effect 
by compressing surrounding tissue. However, a series of 
recent studies suggest instead that enhanced glutamate 
excitability may be the major cause for tumor-associated 
epilepsy. 
More specifically, studies conducted in vitro, in situ, 
and in vivo suggest that glioma cells assiduously release 
glutamate at concentrations that can cause neuronal 
hyperexcitability, edema, and ultimately wide-spread 
tissue destruction [3, 4]. Glutamate is released via the 
system xc
- (SXC) cystine-glutamate exchanger, and 
neuronal death is mediated by MK801 sensitive neuronal 
NMDA receptors [3-5]. Therefore the tumor associated 
destruction is akin to glutamate excitotoxicity, which is 
well described as the major pathway for neuronal demise 
in stroke and ALS [6]. The SXC transporter responsible 
for glutamate release from gliomas is the principle 
pathway for cystine uptake destined for the synthesis 
of the cellular antioxidant glutathione. Hence glutamate 
release from gliomas occurs as an obligatory byproduct 
of the cellular synthesis of GSH [7]. 
A recent study that used a murine glioma model 
suggests that glutamate release from the glioma is 
directly responsible for epileptic activity and represents 
an early event in tumor development [8]. Tissue isolated 
from tumor bearing animals showed increased glutamate 
release and presented with peritumoral hyperexcitability 
that propagated into the adjacent brain. Animals treated 
by i.p. injection with sulfasalazine (SAS), a non-
transportable substrate inhibitor of SXC, showed a 
transient reduction in epileptic activity in vivo, and tissue 
slices from tumor bearing animals showed reduced 
neuronal hyperexcitabiliy after SAS application [8]. This 
data makes a strong case for targeting the SXC transporter 
therapeutically in glioma patients and possibly to consider 
SAS as an available drug candidate. It is important to 
emphasize that the consequences of glutamate release 
are not limited to epileptifom activity but indicate 
active excitotoxic tissue destruction. Therefore limiting 
glutamate release holds promise to also slow tumor 
growth as has been demonstrated in a mouse model of 
glioma [7]. 
Since these findings are based on animal models, 
they  require  confirmation  in  humans.  A  recent  study 
showed that 7/7 glioma patients presented with large 
elevations in glutamate measured by microdialysis, 
confirming an important role for glutamate in the etiology 
and expansion of human gliomas [9]. The fact that SAS 
is widely used to treat a number of chronic inflammatory 
bowl disorders and has a well known safety profile makes 
clinical evaluation in glioma patients readily feasible. Of 
note, SAS has been proposed as a potential candidate to 
treat several other cancers including prostate and small 
lung cell carcinomas [10]. Hence this drug holds promise 
to be useful as adjuvant treatment for a number of cancers. 
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